The cell death response to DNA damage is discussed in this Perspectives piece with cancer as the backdrop because DNA damaging agents (DDA †) are widely used to treat cancer. From decades of clinical results, we learn that DDA have cured some cancers but their toxicity is temporary in most cancers due to emergence of DDA-resistant cancer cells. Investigation of DDA-activated genes, proteins, and pathways, known collectively as the DNA damage response (DDR), has uncovered the inner workings of DDR that protect the genome to sustain life. Paradoxically, however, DDR can also activate death. Current knowledge on DDA-activated death and hypotheses for how DDR may determine when and where to execute death are discussed. Given that cancer cells suffer from DDR defects, which account for their initial sensitivity to DDA, future therapeutic development may exploit those cancer-specific DDR defects to selectively create death-inducing DNA lesions, without using DDA, to kill DDA-resistant cancers.
INTRODUCTION
DNA is the blueprint of life. When that blueprint is irrevocably damaged, life ceases. To stay alive, therefore, requires a continuous effort to protect that blueprint. By its chemical nature, DNA is not inert but highly reactive to elements that are prevalent in the macro-and the micro-environment, e.g., oxygen free radicals or UV light [1] [2] [3] . Hence, living organisms are endowed with a sophisticated toolbox to monitor and repair damages to their DNA. In the evolutionarily conserved parts of this toolbox, we have found proteins, enzymes, and gene products that detect DNA lesions, assemble the appropriate repair machineries, and coordinate a concerted effort from virtually every biological process to achieve the goal of survival, that is, to sustain life. Collectively, these proteins, enzymes and gene products constitute a biological network known as the DNA Damage Response (DDR) [4] . Since DNA is constantly damaged, DDR is constantly deployed. DDR defects are detrimental, for they either cause outright lethality or mutation accumulation to drive diseases, most notably, cancer [4] [5] [6] [7] [8] .
The oncology practice of applying DNA damaging agents (DDA) to treat cancer began empirically in the early 20 th century soon after physicists discovered X-rays [9, 10] . To date, radiation and DNA-damaging drugs have remained the mainstay modality of cancer therapy. The clinical observation that DDA can kill cancer cells supports the idea that DNA damage is detrimental. However, we have now come to appreciate the reason for how oncologists can empirically determine a dose of DDA that kills cancer cells without destroying the body, and that is because cancer cells tend to suffer repair defects and are therefore more likely to be killed by DDA [11] . After a century of advancements and successes in curing a significant number of childhood cancers [12] , DDA have failed to cure the majority of adult cancers because their toxicity is temporary. After the initial destruction of cancer cells by DDA, some malignant cells that survive the insult can resume proliferation and pass the know-how on surviving DDA to their progenies, and thereby neutralizing the toxic effect of radiation and chemotherapy on the recurring cancers. The conclusions that DDR defects drive cancer development and that DDR-defective cells are hypersensitive to DDA are irrefutable [11] ; however, the consistent failure of DDA to cure adult cancer suggests that we may not have fully comprehended the capacity of DDR to sustain life. In the laboratories, biologists have observed cells to adapt to damage by resuming proliferation despite the presence of an irreversible lesion in their DNA [13] [14] [15] [16] [17] . Given that survival is perhaps the strongest selective pressure, it makes sense for DDR to have evolved strategies to sustain life even when DNA damage persists. The fact that we have not been very successful in either preventing or reversing the resistance of recurring cancers to DDA exposes the gaps in our knowledge on the life-sustaining capacity of DDR.
Paradoxically, this life-sustaining DDR also has the capability to actively kill cells [18] [19] [20] [21] [22] . In our body, the genetic blueprint assembled by the fusion of a sperm and an egg is repeatedly copied, i.e., replicated, during development and throughout adult life such that each human DNA blueprint is collectively held by tens of trillions of cells. This multiplicity of the blueprint affords multicellular organisms with the luxury to actively kill off excess or damaged cells [23] , including those with damaged DNA [18] [19] [20] [21] [22] . The cell-killing programs are embedded in the DNA blueprint in that the genomes of multicellular organisms encode proteins and enzymes that when activated can kill cells [23, 24] . Although the death programs are available to every cell of an organism, they are not always activated by DNA damage. For example, in the nematode Caenorhabditis elegans, DNA damage activates death in germ cells but not somatic cells [25] ; and in the developing nervous system of the mouse, DNA damage activates death in neuroblasts but not differentiated neurons [26] . In other words, the death option in DDR is not universalnot all living organisms choose to die in response to DNA damage, and not all cell types in an organism choose to die, either. Obviously, the death programs could not have evolved without the co-evolution of suppressors to keep the killing-machines under wrap [27] . Generally speaking, the death option in DDR is more prevalently activated in cells that are either destined to die or are readily replaceable, such as those in highly regenerative tissues [28] . In this context, active elimination of damaged cells is not only affordable but may also be beneficial to the survival of the organisms [23] . On the whole, however, it is important to emphasize that the death option in DDR is suppressed in most mature tissues of our body.
In this Perspectives piece, I offer what I consider to be well-established death programs that can be activated by DNA damage, and discuss the current knowledge on how cancer cells may suppress these programs to survive radiation and chemotherapy.
TOPICS

MODALITIES OF DNA DAMAGE-INDUCED CELL DEATH
Passive vs Active Death to DNA Damage
The death response to DNA damage falls into two categories: death-from-failure-to-repair vs death-by-choice. The death-from-failure-to-repair is passive; an unintended consequence brought on by detrimental DNA-lesions that interfere with the copying (replication), reading (transcription), and proper functioning (condensation and segregation) of the blueprint. The death-by-choice, in contrast, is an active response, an action brought on by the inner workings of the DDR [22] . Although the passive vs the active death responses are easy to discern on paper, they can be difficult to distinguish experimentally because the death-by-choice is not, and obviously cannot, be immediately activated upon the detection of any DNA lesion. Rather, the active death is a delayed response in DDR and coordinated with the status of DNA repair [20] . Further confounding the experimental categorization of passive vs active death is the finding that death-from-repair-failure, rather than an unintended consequence, may involve necroptosis, which is a killing-machine activated by inflammatory cytokines, oxidative stress, and other metabolic triggers [29] . Given these findings, it would be prudent, for the time being, to consider none of the DNA damage-induced death response to be entirely passive.
Coordination between DNA Repair and Death in DDR
A widely accepted theory posits that DDA activates the death-programs only when DNA-lesions become irreparable. Underlying this theory is the assumption that DDR has the ability to distinguish between a reparable DNA-lesion from one that is irreparable [20, 21] . Although DDR can distinguish between different types of DNA lesions to stimulate the proper repairs of those lesions [20, 30, 31] , there is no evidence that the lesion-detectors can distinguish between those that are reparable from those that are irreparable. In the absence of evidence for the existence of detectors that can recognize irreparable DNA-lesions, we must consider alternative hypoth-eses for how DNA repair may be coordinated with the execution of cell death.
Since the killing-machines must not be activated immediately upon the detection of a DNA lesion, because lesions do occur under normal physiological conditions, there should exist in DDR mechanisms to delay death execution. One such delay mechanism is the built-in requirement for transcription induction and new protein synthesis, which take time, to activate cell death [20, 24] . The requirement for new gene expression to execute death not only provides a safeguard but could also allow for DDR to activate counter-measures to further control the death machines. It is conceivable that DNA lesion-detectors may simultaneously activate DNA-repair, a death-program, and suppressors of that death program ( Figure 1 ). By activating both death and death-suppressors, it would become possible to set a time window for DNA repair (Figure 1 ). In this scenario, it is the combination of repair-efficiency and the death suppressor lifespan that determines the timing of death execution. In this scheme, if DNA-lesions are repaired within the lifespan of death-suppressors, cells do not die ( Figure 1 ). However, if DNA-lesions are not repaired within the lifespan of death-suppressors, death is executed ( Figure 1 ). In cells where DDR does not induce death-suppressors, or in cells where the lifespan of DDR-induced death-suppressors is very short, we would observe a rapid onset of death following exposure to a low dose of DDA, such as the case of embryonic neuroblasts [26, 32] . On the other hand, in cells with constitutively expressed death-suppressors such as mature neurons [33] , death can be prevented despite persistence of DNA-lesions. This idea that DDR can set a window-for-repair, either short or infinite, forgoes the need for detectors of irreparable lesions and negates the requirement for DDR to make judgments on the progress of repair [20] . Rather, in this model, the killing-machines can be pre-set, by the inner workings of DDR in conjunction with the context of a given cell type, for activation after a given window-of-time. While plausible, this theory of a time-dependent regulation of DNA damage-induced death is still pending experimental validation. In DNA damage response (DDR), the detection of DNA-lesion (red star) must not immediately activate cell death because DNA lesions are continuously generated under physiological conditions. Instead, DNA damage-induced cell death is a delayed response, observed after hours and even days following exposure to DNA damaging agents (DDA) [20, 22] . This delay in executing DDA-induced death is often explained by the theory that death is activated only when the DNA-lesions are irreparable. Since there is no evidence for any cellular mechanisms that can distinguish between reparable vs irreparable DNA-lesions [21] , I propose an alternative hypothesis for how DDR can determine when and where to execute cell death. In this hypothesis, DNA damage simultaneously activates DNA repair, death, and death-suppressors (upper panel). Successful repair eliminates the damage and terminates DDR to prevent death, whereas death-suppressors also prevent death execution. By setting the lifespan of death-suppressors, this design of parallel pathway activations pre-sets a window of time for repair (lower panel). During this window of time, DNA damage cannot activate death because of the death suppressors. However, after the decay of death-suppressors, death is activated if the damage is not repaired (lower panel). Of course, if the damaged is repaired before the decay of death-suppressors, death is avoided because DDR is terminated. Cells with a short window-for-repair would be very sensitive to DDA-induced death. On the other hand, with an infinite window-for-repair, cells would become resistant to DDA-induced death.
with the life-sustaining goal of DDR, activated p53 induces the transcription of hundreds of genes to promote survival by: (a) stimulating DNA repair, (b) installing cell cycle checkpoints, and (c) reprograming metabolism [43, 44] . However, the activated p53 also induces the transcription of pro-apoptotic genes to produce PUMA and NOXA proteins [44] [45] [46] [47] . PUMA (product of the human BBC3 gene) and NOXA (product of the human PMAIP1 gene) activate apoptosis by breaking down the anti-apoptosis defense mechanism to cause mitochondrial release of cytochrome C, which activates the apoptosome to stimulate caspases [24, 39] . In mice, knockout of Tp53, or Bbc3 plus Pmaip1, abolished DDA-induced apoptosis in neuroblasts, thymocytes, and other cell types in which apoptosis is an option of DDR [48] [49] [50] . Therefore, the pathway from p53 to PUMA and NOXA is essential to DDA-induced apoptosis (Figure 2 ).
Futile Repair Activates Necroptosis
Necroptosis is a genetic program that, when activated, causes a necrotic form of cell death [29] . Necrotic death, or necrosis, describes the morphology of cell swelling, membrane rupture and the spilling of cell content, which are easily distinguishable from the mor-
Activation of Apoptosis by DNA Damaging Agents (DDA)
The evolutionarily conserved program of apoptosis, when activated, causes cells to condense and fragment their DNA and other content into apoptotic bodies that are recognized and engulfed by neighboring cells or professional phagocytes [34] . During embryonic development, the apoptosis program is deployed to eliminate cells in order to form digits [35] . In the development of immune tolerance, apoptosis is deployed to eliminate self-reactive lymphocytes [36] . Upon infection, apoptosis can be deployed to eliminate infected cells to prevent the spread of pathogens [37] . Biologists have found several different routes to executing the apoptotic form of death [38] . In DDR, activation of apoptosis requires mitochondrial release of cytochrome C to stimulate caspases (Figure 2) , which cleave hundreds of proteins to cause the distinct features of apoptotic death [39] .
Without a doubt, the most important player that enables the apoptosis option in DDR is the transcription factor p53, encoded by the human TP53 gene, with orthologs in other vertebrate species. The p53 protein is a member of the rapid-response-team activated by the master kinases (ATM, ATR, DKN-PK) in DDR [40] [41] [42] . In keeping [40] . The activated p53 stimulates the expression of hundreds of genes, including those encoding PUMA and NOXA, two pro-apoptotic proteins [44] . PUMA and NOXA stimulate apoptosis by causing the release of mitochondrial cytochrome C (Cyt. C), which then stimulates the assembly of apoptosome to activate apoptosis [24] . Tp53 is one of the most frequently mutated genes in cancers, and the loss of p53 disconnects DNA damage to the activation of apoptosis. Futile repair describes the process where a continuous and non-productive repair progress depletes ATP and NAD to cause oxidative stress, which activates the necrosome to stimulate necroptosis [29, 52] . The necrosome can be silenced by the suppression of RIPK3 expression in cancers [51] . In actively proliferating cells, DNA lesions can interfere with DNA synthesis by stalling the replication forks. If cells with incompletely replicated DNA break through G2-arrest to enter mitosis, the condensation of partially replicated sister-chromatids will shatter the DNA to cause mitotic catastrophe [57] . DNA damage-induced growth arrest can sustain life by blocking DNA replication and mitosis to avoid mitotic catastrophe.
minal differentiation [20, 21] . The fact that it is possible for oncologists to empirically determine a DDA dosage that kills cancer cells but does not destroy the brain or the heart is because terminally differentiated neurons and cardiac muscle cells are more resistant to DDA [21, 60] . The therapeutic doses of DDA do kill off normal proliferative cells in the bone marrow, the intestines, or the hair follicles, but these tissues contain sufficient numbers of quiescent stem cells for regeneration after cessation of DDA treatment.
The common characteristic among quiescent, senescent and terminally differentiated cells is the withdrawal from DNA replication. In quiescent cells, the withdrawal is reversible, that is, quiescent cells retain the capacity to initiate DNA replication when the conditions become favorable. In senescent cells, the withdrawal from DNA replication is irreversible and no longer stimulated by growth factors [61] . Because non-proliferative cells do not replicate DNA or enter mitosis, they are less likely to die by mitotic catastrophe (Figure 2 ). Terminally differentiated neurons and muscle cells also express higher levels of apoptosis suppressors [33, 62] . It is of interest to note that necroptosis can still be activated by oxidative stress in aging neurons or cardiac muscle cells [63, 64] , and may account for neural and cardiac toxicity associated with chemotherapy [65, 66] .
Tp53 Mutation in Cancer
The human Tp53 is one of the most frequently mutated genes in cancers; as a result, p53-driven apoptotic response to DNA damage is lost in cancer cells. While p53 induces PUMA and NOXA to activate apoptosis, it is important to point out that p53 also inhibits DNA replication. According to a meta-analysis of published data on p53-target genes, CDKN1A is the most consistently, or universally, induced when p53 becomes activated [44] . CDKN1A encodes the p21CIP1 protein that inhibits Cdk/ Cyclin to enforce G1-arrest, promote senescence and reduce death [67] . The fact that the p53-CDKN1A pathway is also a part of DDR shows that p53-activation alone is not sufficient to determine whether a damaged cell will undergo growth arrest or apoptosis. Despite decades of research and numerous hypotheses [22, 68] , we have not yet arrived at a consensus on how the conflict between the pro-arrest and the pro-apoptosis functions of p53 is resolved in DDR. Obviously, resolution of this conflict is irrelevant to cancer development because Tp53 is mutated in most cancer cells.
PROLIFERATION DESPITE PERSISTENT DAMAGE
Besides the suppression of cell death, recurring cancer cells may also activate strategies to continue prolifphological features of apoptosis [29] . Pathogens or blunt force injuries can rupture the cell membrane to cause necrosis. However, necrotic death can also result from activation of necroptosis, or from the opening of the mitochondrial permeability pore (PTP) [38] . The execution of necroptosis is stimulated by the necrosome, consisting of the RIPK1 and RPIK3 protein kinases, acting at the plasma membrane and in the mitochondria [29, 38] . DNA damaging agents (DDA) can cause necrotic death that requires RIPK1 and RIPK3 [22, 29, 51] . Whereas the master kinases of DDR (ATM, ATR, DNA-PK) directly phosphorylate and activate p53 [40] [41] [42] , there is no evidence as yet for a direct link between the DDR master kinases and the RIPKs. Instead, activation of necroptosis by DDA may result from futile-repair, which describes a continuous but non-productive repair process that can lead to the unintended depletion of ATP and NAD [52] . In other words, activation of necroptosis is an unintended consequence of repair failure (Figure 2 ).
Replication Failure and Mitotic Catastrophe
DNA replication is essential to cell proliferation, tissue regeneration and tumor growth. To ensure the complete and faithful replication of cellular DNA, DDR has a cadre of redundant and robust mechanisms to repair lesions ahead of replication and to re-start replication that is stalled by DNA-lesions [53, 54] . In proliferative cells, upon detection of DNA damage, the DDR master kinases phosphorylate key proteins to prevent the initiation of DNA replication in G1-cells that have not yet committed to DNA synthesis, and this DDR action is referred to as the G1-checkpoint or G1-arrest [20, 55, 56] . In cells that have committed to but not yet completed replication, DDR master kinases phosphorylate other key proteins to prevent the onset of mitosis [20, 55, 56] . This G2-arrest reduces the risk of mitotic catastrophe, where chromosomes are shattered when incompletely replicated sister chromatids become condensed [57] . In the event where DDR fails to enforce G2-arrest while DNA replication forks are stalled, mitotic death would ensue [58, 59] . In other words, the normal process of mitotic chromatin condensation can cause unintended death when DNA lesions prevent the completion of DNA replication ( Figure  2 ).
SUPPRESSION OF DNA DAMAGE-INDUCED CELL DEATH
Quiescence, Senescence, or Terminal Differentiation
Generally speaking, DDA are more likely to kill proliferative than non-proliferative cells, including those in quiescence, senescence, or those that have undergone ter-with a unique arrangement of these DNA [72] and nonunique but efficient repair machines [73] , contribute to the ability of D. radiodurans to reassemble their genetic blueprint even after extensive breakage. One of the phenotypes of malignant cancer cells is aneuploidy, with losses and gains in chromosome copy numbers [74] . The lessons from D. radiodurans suggest that chromosome copy number gains may promote cancer resistance to radiation therapy. The idea that polyploidy can contribute to acquired radio-resistance in cancer is supported by experimental evidence [75, 76] ; however, the mechanisms that drive polyploidy-dependent resistance to radiation therapy have remained to be elucidated.
CONCLUSIONS AND OUTLOOKS
Our knowledge on the cell death response to DNA damage has advanced at a fast pace over the past few decades. Considering that pace, the current gaps in our knowledge on the life-sustaining capacity of DDR will certainly be filled in due course. The important question to ponder, at this time, is how we may apply the knowledge on DNA damage-induced cell death to efficiently and irreversibly kill off cancer cells.
Outlook-1: The field will continue to search for death-suppressors that are activated in recurring cancer cells to block DDA-induced death. Relevant to this line of investigation is the fact that execution of apoptosis or programmed necrosis requires leakage of killer-proteins or calcium ions from the outer or the inner mitochondrial membrane, respectively [38] . Although Tp53 is often mutated in cancer cells, PUMA, NOXA, and other mitochondrial killer-proteins are seldom mutated. Furthermore, cancer cells are dependent on mitochondrial metabolites to support nucleotide biosynthesis and proliferation [77] . Because tumor growth requires mitochondria, and because mitochondria execute death, it is reasonable to assume that mitochondrial protection is enhanced in DDA-resistant cancer cells. The best-known suppressors of mitochondria-dependent apoptosis are the BCL2-family of mitochondrial outer membrane protectors [78] . Drugs have been developed to neutralize the protective functions of BCL2-family members; however, disabling this family of death-suppressors has had limited success in reversing DDA-resistance [79] . Protection of the mitochondrial outer membrane, unfortunately, does not prevent mitochondria permeability transition (MPT), where the opening of the PTP (permeability transition pore) in the inner mitochondrial membrane causes massive leakage of calcium and other metabolites to kill cells [38] . After four decades of investigation, the molecular identify of PTP has remained mysterious [80] , thus hindering the search for suppressors of MPT. While new insights on mitochondrial protection may reveal additional eration despite persistent DNA damage. Several such strategies discovered in unicellular organisms are worth considerations.
Adaptation to Cell Cycle Checkpoints
Cell cycle checkpoints describe DDR-mechanisms that prevent the initiation of DNA replication (G1-checkpoint) or the entry into mitosis (G2-checkpoint) [69] . The checkpoint mechanisms are reversible so that cells can resume proliferation after lesions are repaired. Genetic experiments conducted in the model eukaryotic yeast cells have found that checkpoints are also reversible even when DNA lesions are not repaired. By inducing a double-stranded break (DSB) to activate cell cycle checkpoints in yeast cells that cannot repair DSB, it was found that the repair-defective yeast cells broke through the checkpoints and resumed DNA replication despite the DSB in their DNA [13] . This process of overcoming checkpoints despite lesion-persistence is described as the adaption to DNA damage. In human cancer cells, Tp53 mutation weakens the checkpoints and can thus promote adaptation. Orthologs of Tp53 are not found in yeast, but the yeast genes required for adaptation are conserved through evolution [13] . Hence, DDA-resistant cancer cells could, beyond Tp53 mutation, additionally activate the evolutionarily conserved adaption genes to resume proliferation even when DNA lesions are not repaired.
Lesion-Bypass DNA Replication
In cells that have committed to DNA replication, DDA activates the S-phase checkpoint that inhibits the firing of replication origins, but only temporarily [53] . Thus, the commitment to replicating DNA is accompanied with ways to rapidly adapt to DNA lesions. One such way is to activate DNA polymerases that can synthesize DNA across lesions [70] . These lesion-bypass polymerases are conserved in prokaryotic and eukaryotic cells [70] . Although lesion-bypass DNA synthesis causes mutations, the evolutionary conservation of these enzymes suggests that error-prone replication is preferable to no replication. The human genome encodes over a dozen of lesion-bypass DNA polymerases, which cancer cells can explore to replicate damaged DNA. Such mutagenic DNA synthesis may further drive the emergence of DDA-resistant progenies.
Polyploidy
The bacteria Deinococcus radiodurans, named for extreme resistance to radiation, can withstand radiation doses that shatter their DNA into hundreds of fragments. By sequencing its genome, biologists found D. radiodurans to contain between 4 to 10 genome equivalent of sequences [71] . This redundancy in gene copies, together death suppressors in DDA-resistant cancer cells, we have to consider the possibility that non-proliferating neurons and cardiac muscle cells may also depend on those mitochondrial protectors to survive, as suggested by the fact that defects in mitochondrial quality control underline many forms of neural degenerative diseases [81] . Because DDA-resistant cancer cells may adopt mechanisms that protect neurons and cardiac muscles, there may exist a limit on how far we can push for mitochondria-dependent cell killing in cancer therapy.
Outlook-2:
As an alternative to enforcing mitochondria-dependent cell killing, cancer researchers are exploiting the DDR defects in cancer cells to induce cancer-specific DNA-lesions that can activate mitochondria-independent death. Since the cell cycle checkpoints are weakened and the repair machines are compromised by DDR-defects in cancer, it is plausible to devise strategies, without using DDA, to selectively create death-inducing DNA lesions only in cancer cells [82] . As an example, cancer cells with defects in homologous recombination (HR) repair, due to mutations of BRCA1 or BRCA2, are hypersensitive to DDA [83] . Interestingly, BRCA1-or BRCA2-mutant cells are also sensitive to inhibitors of PARP (poly-ADP-ribose polymerase), which is a DNA-repair enzyme [84] . In patients with HR-defective cancers, PARP inhibitors have delayed cancer progression but they have not improved overall survival [85] . Nevertheless, the success with PARP inhibitors demonstrates that it is possible to design enzyme inhibitors to selectively cause DNA damage in repair-defective cancer cells [86] . Moving forward, it is likely that other enzyme inhibitors will be developed to irreversibly block the replication forks in DDR-defective cancer cells. By combining replication blockade with induction of chromatin condensation, it is possible to kill cancer cells through mitotic catastrophe without the need for apoptosis or necroptosis. Judging from the recent flurry of investigations on replication stress [87] [88] [89] , we look forward to new insights on how to selectively activate replication stress and chromosome fragmentation in DDR-defective and DDA-resistant cancer cells.
